Oxygen in Migraine Treatment

Migraine Headache Clinical Trial

Official title:

The Effectiveness of Supplemental Oxygen Therapy in Patients Receiving Acute Migraine Treatment in the Emergency Department

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05780671
• Other study ID #: E-66175679-514.05.02-1015712
• Status: Recruiting
• Start date: June 1, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: August 2023
• Source: Ankara Ataturk Sanatorium Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

IIn this study, the investigators planned to investigate effectiveness of supplemental oxygen in patients (18-65 years) who were diagnosed as headache related to migraine without aura in the emergency department (ED). Patients who will be ordered standard migraine therapy (50 mg dexketoprofen and 10 mg metoclopramide HCl in 100 cc normal saline IV) by the physician blind to research, will be evaluated by the researchers before the treatment and patients met the study criteria will be included. Included patients randomly divided to two group, study group will receive supplemental oxygen with face mask for 1 hour. Patients' visual analog score (VAS) will be measured at 0th, 15th, 30th and 60th minute of treatment. If there will not be a 50% decrease at VAS score from the beginning, patients will be examined again by the physician again. Patients who will be ordered 100 mg tramadol as rescue therapy by the physician, will be continued to observed, VAS scores will be measured at 120th minute again. To avoid drug related bias, patients who will be ordered any other drug for primary care or rescue treatment other than mentioned above will not be included into the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

with their medical history and ED evaluation being diagnosed as migraine related headache according to HIS 2018 classification, having VAS >40 at the beginning of the treatment, accepting to participate patient group who received standard migraine therapy (50 mg dexketoprofen and 10 mg metoclopramide HCl in 100 cc normal saline iIV). patient who received 100 mg tramadol as rescue therapy Exclusion Criteria: Taking any analgesic in 6 hours before admission, patients who were diagnosed with all other types of primary headaches (migraine with aura, migraine status, TTH, trigeminal autonomic cephalgia etc), patients using anticoagulants or have bleeding diathesis, pregnant and breastfeeding patients, patients had fever, patients diagnosed as secondary headaches, patients had focal neurologic findings, patients had heart, liver, or kidney failure, patients had peptic ulcer, patients had chronic obstructive pulmonary disease, patients had acute coronary syndrome, patients who were not stable hemodynamically patients who had history of acute dystonia or akathisia due to metoclopramide. -

Related Conditions & MeSH terms

• Headache
• Migraine Disorders
• Migraine Headache
• Oxygen

Intervention

Other:
• oxygen
inhaled oxygen 10L/min with face mask for 1 hour

Locations

Country	Name	City	State
Turkey	University of Health Sciences Ankara Ataturk Sanatorium TRH	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Ankara Ataturk Sanatorium Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	examine effect of oxygen therapy in pain management of acute migraine attacks in emergency department.	comprasion of VAS scores	until December 2023
Secondary	Rate of pain relief and need for additional analgesics were determined as secondary outcomes to be evaluated.		until december 2023